We further demonstrated that the AURKA and FOXM1 inhibitors can function synergistically to inhibit AURKA activity and disrupt the positive feedback loop to more effectively limit the tumorigenicity of breast cancer cells. The gene discussed is FOXM1; the disease is breast carcinoma.